ANIX

Anixa Biosciences, Inc. (ANIX) 10Y Growth Potential Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 3.2 (Weak)

ANIX lacks disclosed 5-year revenue, EPS, or FCF CAGR data, limiting evidence of repeatable compounding versus peers with clearer multi-year growth records.

Negative TTM ROIC of -79.6% indicates current capital deployment is not translating into scalable revenue expansion, unlike stronger peer growth platforms.

Near-zero leverage does preserve balance-sheet flexibility, but without proven operating growth it does not materially improve long-term revenue compounding capacity.

The absence of segment concentration data prevents evidence that any product or customer base is already scaling faster than direct peers.

Market Tailwinds

Score:

No filing-based evidence here shows durable demand acceleration, so ANIX cannot be credited with the structural tailwinds visible in stronger peer growth stories.

The company’s current metrics suggest growth depends more on future execution than on an already-proven expanding market opportunity versus peers.

Negative profitability and missing growth history imply limited proof that external demand is converting into sustained revenue expansion at scale.

Compared with peers that show recurring top-line momentum, ANIX currently lacks documented indicators of multi-year market-driven compounding.

Scalability Expansion

Score:

Negative ROIC and absent revenue CAGR evidence suggest reinvestment is not yet producing scalable expansion, unlike higher-quality peer compounders.

Zero reported capex and R&D intensity may reflect limited investment, but it also provides no proof of a scalable growth engine.

The extremely negative cash conversion cycle is not a reliable scalability signal here, because it may reflect data distortion rather than durable operating leverage.

Relative to peers with demonstrated operating leverage, ANIX shows weak evidence that incremental capital can be repeatedly converted into revenue growth.

Constraints Limitations

Score:

The main constraint is the lack of disclosed multi-year growth evidence, which makes long-term scalability harder to validate than for peer companies.

Negative ROIC indicates current economics are structurally unproven, limiting confidence that growth can compound without continued dilution or external support.

Missing segment and margin history reduces visibility into whether any business line can scale faster than peers over a decade.

While leverage is low, the larger limitation is execution proof, because capital flexibility alone cannot offset absent evidence of durable expansion.

Overall Score

Score:

ANIX currently shows limited evidence of durable, scalable revenue compounding, and its negative ROIC plus missing growth history place it well below stronger peer growth profiles.

Score Driver: Negative ROIC

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Anixa Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →